Finch Therapeutics Group (FNCH) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Finch Therapeutics Group, Inc. faces a challenge as Nasdaq has flagged it as a “public shell,” questioning the legitimacy of its operational business and suggesting a delisting. While the company contests this, seeking an appeal that delays any immediate delisting consequence, uncertainty looms over its future on the exchange. Additionally, ongoing patent litigation with Rebiotix Inc. and Ferring Pharmaceuticals further complicates Finch’s situation, with the trial now postponed to August 2024.
For further insights into FNCH stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money